Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Antioxidant Therapy in Diabetic Retinopathy
NCT03702374Phase 3Completed
- Sponsor
- Universidad de Guadalajara
- Start
- Sep 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in diabetic retinopathy (DR) (2 arms), sponsored by Universidad de Guadalajara. Primary endpoints: Changes in concentration of serum malondialdehyde at 12 months, Changes in ATPase activity at 12 months and 1 more. Started Sep 2018; status: completed.
02
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03702374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702374.